Lunit is a medical AI company dedicated to conquering cancer. It provides AI-powered solutions for cancer diagnostics and therapeutics, helping clinicians detect early-stage cancer with greater accuracy and predict patient response to treatment. Its products analyze medical images and tissue data to improve clinical outcomes.
An AI-powered radiology platform designed to assist medical professionals in analyzing chest X-rays (CXR) and lung CT scans. It enhances diagnostic accuracy and efficiency by automatically detecting up to 148 pathologies, including lung nodules and tuberculosis, and seamlessly integrating into existing clinical workflows.
Lunit is a medical AI company dedicated to conquering cancer. It provides AI-powered solutions for cancer diagnostics and therapeutics, helping clinicians detect early-stage cancer with greater accuracy and predict patient response to treatment. Its products analyze medical images and tissue data to improve clinical outcomes.
An AI-powered radiology platform designed to assist medical professionals in analyzing chest X-rays (CXR) and lung CT scans. It enhances diagnostic accuracy and efficiency by automatically detecting up to 148 pathologies, including lung nodules and tuberculosis, and seamlessly integrating into existing clinical workflows.
| Feature | Lunit | Rayscape |
|---|---|---|
| Primary category | Predictive Analytics | Diagnostics |
| Added | 2025-08-02 | 2025-08-07 |
| Pricing | Not verified | Not verified |
| Official website | www.lunit.io | rayscape.ai |
| Product type | Website | Website |
| Performance data | ||
| User rating | Not verified | Not verified |
| Comments | 0 | 0 |
| Monthly visits | 38.4K | 6.5K |
| Monthly growth | -7.6% | -14.3% |
| Favorites | 85 | 99 |
| Details | View details | View details |
Compare Lunit and Rayscape by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
In the Lunit vs Rayscape monthly traffic comparison, Lunit currently shows 38.4K visits and Rayscape shows 6.5K; Lunit has about 5.9 times the visible traffic of Rayscape, an absolute difference of about 31.8K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
Lunit is registered at the www.lunit.io/en subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 36.04% | 13.8K |
| 🇰🇷Korea, Republic of | 25.34% | 9.7K |
| 🇮🇳India | 16.94% | 6.5K |
| 🇻🇳Vietnam | 14.38% | 5.5K |
| 🇹🇷Turkey | 7.3% | 2.8K |
| Source type | Percentage | Traffic |
|---|---|---|
| Direct | 92.51% | 35.5K |
| Referral | 5.74% | 2.2K |
| 1.75% | 671 |
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 39.64% | 2.6K |
| 🇹🇷Turkey | 30.2% | 2K |
| 🇮🇳India | 30.16% | 2K |
This in-depth Lunit vs Rayscape comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. Lunit is primarily listed under “Predictive Analytics”, while Rayscape is primarily listed under “Diagnostics”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (Lunit: Predictive Analytics; Rayscape: Diagnostics); Monthly visits (Lunit: 38.4K; Rayscape: 6.5K); Monthly growth (Lunit: -7.6%; Rayscape: -14.3%); Favorites (Lunit: 85; Rayscape: 99); Website (Lunit: www.lunit.io; Rayscape: rayscape.ai). These facts are more useful for selection than brand visibility alone.
In the Lunit vs Rayscape monthly traffic comparison, Lunit currently shows 38.4K visits and Rayscape shows 6.5K; Lunit has about 5.9 times the visible traffic of Rayscape, an absolute difference of about 31.8K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
Lunit is registered at the www.lunit.io/en subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
Lunit is registered under a www.lunit.io subpath, so its large visible total may include the host platform. The current data does not justify choosing Lunit for traffic alone; shortlist by unique taxonomy and use case, then validate with the same tasks.
Lunit and Rayscape currently overlap in shared categories: Medical Imaging; shared tags: AI diagnostics, healthcare AI, medical imaging, and radiology. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
Lunit's unique categories/tags are Predictive Analytics, Oncology, biomarker, cancer detection, deep learning, immunotherapy, and oncology; Rayscape's are Diagnostics, Data Analysis, chest x-ray, clinical decision support, lung CT, lung nodule detection, and tuberculosis detection. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
Lunit has no verified rating, 0 comments, 85 favorites, and 87 likes；Rayscape has no verified rating, 0 comments, 99 favorites, and 92 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Put Lunit on the priority trial list when the task aligns with “Predictive Analytics” and especially Predictive Analytics, Oncology, biomarker, cancer detection, deep learning, and immunotherapy. This follows recorded positioning and does not imply unlisted capabilities are absent.
Lunit also currently records: pricing is not verified, product type is website, 38.4K monthly visits shown for the registered host (subpage scope unknown), no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
Put Rayscape on the priority trial list when the task aligns with “Diagnostics” and especially Diagnostics, Data Analysis, chest x-ray, clinical decision support, lung CT, and lung nodule detection. This follows recorded positioning and does not imply unlisted capabilities are absent.
Rayscape also currently records: pricing is not verified, product type is website, 6.5K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in Lunit and Rayscape, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.
